Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study

BACKGROUND: 52-week results from C-axSpAnd demonstrated the safety and efficacy of certolizumab pegol (CZP) in patients with active non-radiographic axial spondyloarthritis (nr-axSpA) and objective signs of inflammation (sacroiliitis on MRI and/or elevated C-reactive protein levels). Long-term safet...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Heijde, Désirée, Gensler, Lianne S, Maksymowych, Walter P, Landewé, Robert, Rudwaleit, Martin, Bauer, Lars, Kumke, Thomas, Kim, Mindy, Auteri, Simone Emanuele, Hoepken, Bengt, Deodhar, Atul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Spondyloarthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928377/
https://www.ncbi.nlm.nih.gov/pubmed/35296532
http://dx.doi.org/10.1136/rmdopen-2021-002138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928377/
https://www.ncbi.nlm.nih.gov/pubmed/35296532
http://dx.doi.org/10.1136/rmdopen-2021-002138

Ejemplares similares